Join our Community
Support ToI and remove all ads
Learn more

ISRAEL AT WAR - DAY 653

Roche

Illustrative. A cancer patient receives chemotherapy treatment. (via Shutterstock)
August 16, 2020, 12:18 pm
KAHR Medical gets FDA nod to start human trials for cancer drug
Drug developed by Jerusalem-based startup targets cancer cells, weakens their defenses, and activates a local response, company says; Swiss pharma firm Roche to join trials
By Shoshanna Solomon
lllustrative. A lab technician does research in a lab. (appledesign; iStock by Getty Images)
August 10, 2020, 3:03 pm
Swiss giant Roche seeks to invest in early-stage Israeli health-tech startups
Roche jointly sets up investment program with Israeli life-sciences VC fund aMoon, with the aim to speed up the development of new diagnostic technologies from Israel
By Shoshanna Solomon
Illustrative: A cancer patient and a perfusion drip. (CIPhotos, iStock by Getty Images)
September 15, 2019, 2:15 pm
Startup joins Roche to hold clinical trials for double-whammy cancer drug
DSP-107, developed by KAHR Medical, hopes to have dual impact: tag cancer cells, and boost activity of the immune cells that target them
By Shoshanna Solomon
A nurse uses a digital health app (Courtesy)
From the WebApril 22, 2018, 5:48 pm
General Electric, Roche mull Israel, Finland for joint research site
Calcalist: The two companies are in talks with Israel’s Innovation Authority, people familiar with the matter say
Load More
Sign in or Join The Times of Israel Community
Paying ToI Community members are invited to comment on articles
Please use the following structure: example@domain.com
Or Continue with
By joining you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Join The Times of Israel Community
Only ToI Community members can comment below articles
Forgot your password? / Send me a login link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering allows you to manage your newsletters and alerts and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.